Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4139 in Healthy Participants
NCT07802964Phase 1Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Psoriasis vulgaris (PV) comparing HRS-4139 tablet group with HRS-4139 placebo group (2 arms). Primary endpoints: Adverse events at Day 72 and Serious Adverse events at Day 72. Started Sep 2026; status: recruiting.
02
Drugs
HRS-4139
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT07802964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802964.